An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension

Torvik, D.; Madsbu, Hans-Petter

doi:10.1016/0002-9149(87)90160-3

Cited by 29 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intolerable side effects occurred in only a few patients. The dropout rate was comparable to that reported in earlier long-term studies of a 1-blockers (8,9). The results of the present study provide further evidence that doxazosin is an effective and well tolerated antihypertensive drug.…”

Section: Resultssupporting

confidence: 89%

Long-Term Effects of Doxazosin, an Alpha1-Blocker, on Serum Lipids in Hypertensive Patients.

et al. 1996

View full text Add to dashboard Cite

Nowadays practical antihypertensive therapy involves not only simple normalization of blood pressure but also a reduction of the risks of cardiovascular disease.In this multicenter open-label study, the longterm effects of doxazosin, an al-adrenergic receptor blocker, on serum lipids were prospectively investigated in 253 patients with essential hypertension. They were treated with doxazosin for 1 year. The averaged blood pressure was maintained at levels lower than 150190 mmHg throughout 1 year, but heart rate did not increase. After 3 months of doxazosin therapy, total and low density lipoprotein-cholesterol levels in serum were significantly reduced by 3.3% and 3.4% , respectively, and these levels were maintained throughout the study period. This effect of doxazosin on serum lipids was especially prominent in patients with hypercholesterolemia.In addition, the lipid profile of these patients was favorably altered even when other antihypertensive drugs or lipid-lowering drugs had already been used or were used concurrently.These results constitute useful information for physicians who treat hypertension with alblockers to reduce the overall risk of cardiovascular disease. (Hypertens Res 1996; 19: 43-49)

show abstract

Section: Resultssupporting

confidence: 89%

Long-Term Effects of Doxazosin, an Alpha1-Blocker, on Serum Lipids in Hypertensive Patients.

et al. 1996

View full text Add to dashboard Cite

show abstract

“…Experience thus far available suggests that the successor drugs to prazosin, in particular doxazosin and terazosin, cause less postural hypotension than prazosin, and it has been claimed that doxazosin would not display this problem at all [39,40]. This difference with prazosin may be explained by the slower onset of the hypotensive effects of doxazosin and terazosin.…”

Section: Radrenaline Levels a Rise In Heart Rate And Contractility mentioning

confidence: 99%

Drugs interacting with alpha adrenoceptors

Zwieten

1989

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Alpha adrenoceptors should be divided into various subtypes, comprising pre/postsynaptic and alpha 1/alpha 2-subpopulations, respectively. This classification implicates important functional differences between the various alpha-receptor subtypes, including certain differences in signal transduction following receptor stimulation. After a brief synopsis of the modern classification of alpha-adrenoceptors and its functional implications, the emphasis of the present survey is laid upon the various drugs that interact with the different alpha-adrenoceptor subtypes. Accordingly, agonists and antagonists towards alpha 1- and alpha 2-adrenoceptors are discussed with respect to the pharmacologic basis of their therapeutic activity. Some attention is paid to alpha 1-adrenoceptor antagonists with additional pharmacological activities, e.g., labetalol, ketanserin, and urapidil. Finally, the indirect and rather subtle interaction of calcium antagonists and ACE inhibitors with alpha-adrenoceptor-triggered vasoconstriction is also dealt with, in particular with respect to the influence of these drugs on receptor-operated calcium channels and signal transduction following receptor stimulation.

show abstract

“…Many double-blind and open trials in hypertension have confirmed that terazosin and doxazosin are effective once-daily as monotherapy (94)(95)(96)(97)(98)(99)(100)(101)(102)(103)(104)(105). Little work has been done with combinations of doxazosin and other antihypertensive agents, but terazosin is (102)(103)(104)(105)107).…”

Section: Eficacy Of Terazosin and Doxazosin In Hypertensionmentioning

confidence: 99%

“…Table 3 compares the two a-1 inhibitors with their parent compound prazosin, with atenolol, hydrochlorothiazide, and each other. As monotherapy, both drugs are equipotent and at least as effective as prazosin (44,97,101). In comparison with hydrochlorothiazide, the diuretic seems marginally more powerful than either a-1 blocker (44,96,99).…”

Section: Eficacy Of Terazosin and Doxazosin In Hypertensionmentioning

confidence: 99%

See 1 more Smart Citation

Alpha-1 Blockers. A New Generation of Antihypertensive Agents

Humphreys

Waite

1989

J Clin Pharm Ther

View full text Add to dashboard Cite

SUMMARYAlpha-1 blockers have certain disadvantages over conventional and antihypertensive therapies in their haemodynamic profile and metabolic effects.This paper reviews the development of a-blockade, the therapeutic efficacy of prazosin, the prototype a-1 blocker, and the rationale for the oncedaily antihypertensive compounds, terazosin and doxazosin. These drugs offer a useful alternative to first-or second-line therapy in suitable hypertensive patients, particularly with their potentially beneficial effects on serum lipids.

show abstract

An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension

Cited by 29 publications

References 18 publications

Long-Term Effects of Doxazosin, an Alpha1-Blocker, on Serum Lipids in Hypertensive Patients.

Long-Term Effects of Doxazosin, an Alpha1-Blocker, on Serum Lipids in Hypertensive Patients.

Drugs interacting with alpha adrenoceptors

Alpha-1 Blockers. A New Generation of Antihypertensive Agents

Contact Info

Product

Resources

About